Article

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna, Italy.
Annals of Oncology (impact factor: 6.43). 02/2010; 21(9):1877-83. DOI:10.1093/annonc/mdq024 pp.1877-83
Source: PubMed

ABSTRACT The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL). Materials and methods: We retrospectively analyzed data from 59 relapsed or refractory FL patients treated with ibritumomab tiuxetan Y 90 in four different PET centers who had a PET scan carried out before and after RIT. Possible predictive factors of progression-free survival (PFS) were studied through univariate and multivariate analysis.
The post-RIT PET documented 45.8% complete responders (CR), 25.4% partial responders (PR) and 28.8% nonresponders [stable disease + progressive disease], with an overall survival of 71.2% (range 59.5%-90.9%). With a median follow-up period of 23 months, the univariate analysis documented a statistically significant relation between disease extent before RIT and response to treatment with respect to PFS (P = 0.015), while all the other prognostic factors showed no significant correlation. When carrying out the multivariate analysis, post-RIT PET resulted as the lonely independent predictor of PFS (P < 0.00001).
RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor.

0 0
 · 
0 Bookmarks
 · 
22 Views
  • Source
    Article: Imaging in follicular NHL.
    M S Hofman, R J Hicks
    [show abstract] [hide abstract]
    ABSTRACT: Imaging contributes to management of follicular lymphoma (FL) through guiding biopsy, determining disease stage and assessing therapeutic response. Molecular imaging with positron emission tomography (PET), especially when combined with computer tomography (PET/CT), is more accurate than conventional imaging and extends the role of imaging to lesion characterisation, including non-invasive assessment of high-grade transformation. There is strong data to support the use of FDG PET/CT for primary staging, resulting in significant management change. In patients with early stage follicular lymphoma (stage I or II), there is a clear role for PET/CT to avoid futile involved-field radiotherapy in patients with widespread disease and to optimise the treatment field in patients with confirmed localised disease. For restaging, use of PET/CT allows discrimination between scar tissue and viable tumour in residual masses. Molecular imaging is likely to play an increasing role in selection of patients for specific treatments and in prognostic stratification.
    Best practice & research. Clinical haematology 06/2011; 24(2):165-77. · 3.13 Impact Factor
  • Source
    Article: Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?
    Vit Prochazka, Tomas Papajik, Marie Jarosova, Karel Indrak
    [show abstract] [hide abstract]
    ABSTRACT: Follicular lymphoma accounts for about 20-30% of non-Hodgkin's lymphomas. Clinical behaviour and overall prognosis are highly variable, ranging from indolent forms with occasional spontaneous remissions to rapidly progressive disease. Modern treatment strategies have shifted from a primarily "palliative" approach to more intensive risk-adapted therapy with the intention of achieving complete long-term remission. New targeted treatment with monoclonal antibodies (MoAb) and radioimmunoconjugates (RIT) has resulted in unprecedented improvements in treatment outcome. At the same time, a large amount of information is now available on lymphomagenesis, the role of the microenvironment of lymphomatous follicles and cytogenetic abnormalities. We can better understand the role of the patient's innate anti-lymphoma immunity. Although no standard front-line therapy has been established, increasingly more data show that risk-adapted treatment strategy have survival benefits for high-risk patients. For this reason, accurate prognostic indices are urgently needed to find optimal therapies for particular lymphoma patients. Whereas the currently used FLIPI index was established in the pre-rituximab era, the newly designed FLIPI 2 index still needs to be confirmed in prospective trials. New therapeutic approaches with MoAb, RIT and other biological agents allow the population to be divided into increasing numbers of groups with different outcomes. All in all, in the near future, we will probably not use only one basic prognostic index for all populations of FL patients. New prognostic schemes should analyze patients separately and include both disease- and patient/host-related parameters.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 06/2011; 155(2):99-108.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

23 months
 
25.4% partial responders
 
59 relapsed
 
different PET centers
 
effective therapy
 
FDG)-positron emission tomography
 
FL patients
 
ibritumomab tiuxetan Y 90
 
independent predictive factor
 
lonely independent predictor
 
median follow-up period
 
multivariate analysis
 
non-Hodgkin's follicular lymphoma
 
Possible predictive factors
 
post-RIT PET
 
post-RIT PET result
 
prognostic factors
 
refractory FL patients
 
statistically significant relation
 
univariate analysis documented